Alkermes Plc SVP Michael J. Landine Unloads 10,000 Shares (ALKS)
Alkermes Plc (NASDAQ:ALKS) SVP Michael J. Landine sold 10,000 shares of the stock in a transaction dated Thursday, June 19th. The shares were sold at an average price of $47.01, for a total transaction of $470,100.00. Following the transaction, the senior vice president now directly owns 130,521 shares of the company’s stock, valued at approximately $6,135,792. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Alkermes Plc (NASDAQ:ALKS) traded up 5.71% during mid-day trading on Friday, hitting $50.88. The stock had a trading volume of 2,464,335 shares. Alkermes Plc has a one year low of $26.47 and a one year high of $54.25. The stock’s 50-day moving average is $46.35 and its 200-day moving average is $45.70. The company’s market cap is $7.353 billion.
Alkermes Plc (NASDAQ:ALKS) last released its earnings data on Wednesday, April 30th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the previous year, the company posted $0.40 earnings per share. The company’s revenue for the quarter was down 20.3% on a year-over-year basis. On average, analysts predict that Alkermes Plc will post $0.49 earnings per share for the current fiscal year.
ALKS has been the subject of a number of recent research reports. Analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, May 2nd. They now have a $50.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alkermes Plc from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 16th. They now have a $45.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $49.50.
Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.